| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 14 | 2023 | 119 | 6.110 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 294 | 3.500 |
Why?
|
| HIV Infections | 16 | 2023 | 1899 | 2.350 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 144 | 2.280 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 676 | 2.180 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 47 | 1.650 |
Why?
|
| Lymphoma | 4 | 2023 | 323 | 1.560 |
Why?
|
| Malawi | 17 | 2025 | 398 | 1.370 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 225 | 1.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 164 | 1.230 |
Why?
|
| Histiocytosis, Langerhans-Cell | 4 | 2024 | 221 | 1.220 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 146 | 1.210 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2025 | 14 | 0.950 |
Why?
|
| Child | 41 | 2025 | 24559 | 0.930 |
Why?
|
| Organ Transplantation | 2 | 2024 | 168 | 0.910 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 144 | 0.810 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.810 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 63 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 1256 | 0.690 |
Why?
|
| Adolescent | 27 | 2025 | 19441 | 0.670 |
Why?
|
| Interleukin-6 | 2 | 2019 | 420 | 0.670 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 299 | 0.650 |
Why?
|
| Anemia | 2 | 2023 | 339 | 0.640 |
Why?
|
| Viral Load | 4 | 2018 | 389 | 0.600 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 267 | 0.590 |
Why?
|
| Cytokines | 3 | 2021 | 1289 | 0.570 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 142 | 0.560 |
Why?
|
| Humans | 53 | 2025 | 125667 | 0.520 |
Why?
|
| Vincristine | 5 | 2020 | 193 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1705 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 2 | 2025 | 141 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1204 | 0.390 |
Why?
|
| Rituximab | 3 | 2024 | 159 | 0.390 |
Why?
|
| Child, Preschool | 16 | 2025 | 14106 | 0.390 |
Why?
|
| Neoplasms | 4 | 2025 | 2803 | 0.380 |
Why?
|
| Methotrexate | 3 | 2025 | 334 | 0.380 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 3 | 0.350 |
Why?
|
| Male | 27 | 2025 | 61776 | 0.330 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 136 | 0.320 |
Why?
|
| Disease Management | 2 | 2025 | 532 | 0.320 |
Why?
|
| Young Adult | 12 | 2024 | 9093 | 0.310 |
Why?
|
| Female | 27 | 2025 | 66998 | 0.300 |
Why?
|
| Tanzania | 3 | 2023 | 69 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 504 | 0.280 |
Why?
|
| Prognosis | 6 | 2025 | 4690 | 0.280 |
Why?
|
| Bone Marrow | 3 | 2021 | 325 | 0.270 |
Why?
|
| Immunotherapy | 4 | 2022 | 680 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2025 | 6171 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1278 | 0.260 |
Why?
|
| Retrospective Studies | 9 | 2025 | 16417 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 20 | 0.240 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 862 | 0.230 |
Why?
|
| Infant | 9 | 2025 | 12572 | 0.230 |
Why?
|
| Doxorubicin | 3 | 2020 | 290 | 0.220 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 871 | 0.210 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 185 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.210 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 418 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12420 | 0.210 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 14 | 0.210 |
Why?
|
| HIV-1 | 2 | 2016 | 465 | 0.200 |
Why?
|
| Adult | 9 | 2024 | 29734 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 19 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 249 | 0.200 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 258 | 0.200 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 114 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 316 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 373 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 360 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2023 | 219 | 0.190 |
Why?
|
| Perforin | 1 | 2021 | 17 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 329 | 0.170 |
Why?
|
| Virus Replication | 1 | 2023 | 607 | 0.170 |
Why?
|
| Cysticercosis | 1 | 2020 | 22 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 199 | 0.170 |
Why?
|
| Bleomycin | 2 | 2020 | 154 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 62 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 545 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 30 | 0.160 |
Why?
|
| Anthracyclines | 2 | 2017 | 36 | 0.160 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 21 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 265 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 54 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 321 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 87 | 0.150 |
Why?
|
| Biopsy | 1 | 2021 | 1241 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 69 | 0.140 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 292 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 108 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 99 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 357 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 180 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 758 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 271 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 300 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3439 | 0.120 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.120 |
Why?
|
| Algorithms | 1 | 2021 | 1632 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10340 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1397 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1727 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 334 | 0.110 |
Why?
|
| Child Health Services | 1 | 2013 | 87 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 193 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3095 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 71 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1160 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 508 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 221 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3174 | 0.090 |
Why?
|
| Recurrence | 2 | 2024 | 1420 | 0.080 |
Why?
|
| United States | 2 | 2023 | 10942 | 0.080 |
Why?
|
| Survival Rate | 4 | 2017 | 2073 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8249 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 480 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 1516 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1106 | 0.080 |
Why?
|
| Transcriptome | 1 | 2014 | 973 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1901 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 5893 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 783 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3396 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2356 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5195 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 233 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1912 | 0.070 |
Why?
|
| Prednisone | 2 | 2019 | 277 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6351 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4585 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 907 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2019 | 379 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 41 | 0.060 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 32 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 79 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2025 | 171 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 102 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 208 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1526 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 235 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 193 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 300 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 122 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 239 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 391 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 325 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 568 | 0.040 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 3 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 11 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 172 | 0.040 |
Why?
|
| Taenia solium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 192 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 29 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 130 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 27000 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 235 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 294 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 781 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1273 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 140 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 34 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1175 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 128 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 129 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 455 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1013 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 37 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 3470 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2604 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 177 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 204 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1365 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 236 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Botswana | 1 | 2013 | 75 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1333 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 75 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1561 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 84 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 608 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1288 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1749 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 772 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 226 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 34349 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3155 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 133 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 483 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1751 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 667 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 230 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2831 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 538 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1075 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1033 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 768 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 534 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 801 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7223 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 543 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1248 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1590 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 17727 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1201 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1706 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19900 | 0.020 |
Why?
|